CareCloud Wins AI Platform Project With KabaFusion for Home Infusion Operations

Key Points

• CareCloud will develop LailaCare, a customized AI-powered platform for KabaFusion’s home infusion and specialty pharmacy operations.
• The platform is intended to combine referral intake, insurance eligibility and authorization, patient engagement, and revenue-cycle management into one system.
• AI is expected to route referrals, support authorization workflows, and review claims to help reduce denials, while KabaFusion staff retain control of clinical and exception decisions.
• KabaFusion serves patients in 49 states through home infusion pharmacies, ambulatory infusion suites, and home-health agencies.
• The companies did not disclose contract value, implementation timing, recurring revenue terms, or financial guidance related to the project.

CareCloud, Inc. (Nasdaq: CCLD) has been selected by KabaFusion to design and develop LailaCare, an AI-powered operating platform for home infusion and specialty pharmacy services. KabaFusion will own the platform, while CareCloud will build the technology to unify intake, authorization, patient engagement, and revenue-cycle workflows.

LailaCare Is Designed to Simplify Home Infusion Workflows

KabaFusion selected CareCloud to create a single digital platform that brings together several steps required to begin and manage home infusion treatment. These steps include receiving a referral, verifying insurance coverage, obtaining payer authorization, communicating with patients, and submitting claims for payment.

The goal is to reduce manual administrative work and speed up patient onboarding. In home infusion, delays in referrals, benefit verification, or insurance approvals can postpone treatment. A more connected workflow may help KabaFusion coordinate care more efficiently while giving patients clearer access to information about their treatment journey.

AI Will Support Referral Routing and Claims Management

Artificial intelligence will be built into LailaCare’s operational processes. The companies said the platform is designed to identify and direct referrals during intake, assist with eligibility and authorization tasks, and review claims before submission to help prevent denials.

CareCloud and KabaFusion emphasized that trained KabaFusion personnel will remain responsible for clinical decisions and exceptions. The platform is intended to support staff rather than independently make treatment decisions.

For CareCloud, the project expands the use of its AI and healthcare-technology capabilities in a specialized care setting. The company already provides revenue-cycle management, practice-management, electronic-health-record, business-intelligence, patient-experience, and digital-health services to more than 40,000 healthcare providers.

KabaFusion Adds a Technology Layer to National Infusion Network

KabaFusion is a national provider of chronic and acute infusion therapies, delivering care through home infusion pharmacies, ambulatory infusion suites, and home-health agencies. The company operates across 49 states and works with patients, healthcare providers, and payers before, during, and after treatment.

The LailaCare platform is intended to modernize the company’s operational systems as it manages a large network of specialty pharmacy and infusion-care services. If successfully deployed, the technology could help KabaFusion improve staff productivity, reduce administrative friction, support faster patient access, and strengthen billing operations. These outcomes are goals, not reported results.

Investors Await Financial Terms and Implementation Updates

The partnership gives CareCloud a notable healthcare-technology development project and supports its strategy to expand AI-enabled offerings. However, investors do not yet know the project’s contract value, delivery schedule, margin profile, or whether it will generate recurring revenue after development is complete.

For CCLD investors, the key follow-up items include implementation milestones, potential revenue recognition, customer expansion opportunities, measurable reductions in claim denials or onboarding time, and whether CareCloud can use the LailaCare platform as a model for additional home infusion and specialty pharmacy clients.